Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virus tracking in kidney transplants may spot hidden risks

NCT ID NCT04189835

Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 509 kidney transplant recipients to see if regularly measuring Epstein-Barr virus (EBV) levels in blood could predict serious infections, a type of cancer called PTLD, or death. Researchers compared virus levels in whole blood versus plasma to find the best way to monitor patients. The goal was to learn whether persistent EBV DNA could signal that a patient's immune system is too suppressed, helping doctors personalize treatment in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

509 people

The number who actually took part.

Started

Jan 2020

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with end-stage renal disease in the southern part of Norway and in the western part of Denmark qualified to undergo kidney transplantation.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children from 2 years of age receiving a kidney transplant from a living or deceased donor. * Adults 18 years or older who receive a kidney transplant from a living or deceased donor. * Capable of giving written informed consent to participation in the study (legal guardians capable of giving written informed consent to participation in the study in case of children younger than 18 years old). Exclusion Criteria: * Patients unable to comply with the study requirements. * Withdrawal of consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection Epstein-Barr virus-associated lymphoproliferative disorder post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV infection EBV viremia Epstein-Barr virus associated lymphoproliferative disorder Post-transplant lymphoproliferative disorder

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, Central Region Denmark, Denmark

  • Odense University Hospital

    Odense, Region Syddanmark, Denmark

  • Rikshospitalet, Oslo Universitetssykehus

    Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.